143 related articles for article (PubMed ID: 34871036)
21. Cancer Care by Committee to be Superseded by Personal Physician-Patient Partnership Informed by Artificial Intelligence.
Turner JH
Cancer Biother Radiopharm; 2023 Oct; 38(8):497-505. PubMed ID: 37366774
[TBL] [Abstract][Full Text] [Related]
22. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
23. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
24. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
25. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
Batra JS; Niaz MJ; Whang YE; Sheikh A; Thomas C; Christos P; Vallabhajosula S; Jhanwar YS; Molina AM; Nanus DM; Osborne JR; Bander NH; Tagawa ST
Urol Oncol; 2020 Nov; 38(11):848.e9-848.e16. PubMed ID: 32600929
[TBL] [Abstract][Full Text] [Related]
27. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
28. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
29. Early Prostate-Specific Antigen Changes and Clinical Outcome After
Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
[TBL] [Abstract][Full Text] [Related]
30. An Impressive Approach in Nuclear Medicine: Theranostics.
Vahidfar N; Eppard E; Farzanehfar S; Yordanova A; Fallahpoor M; Ahmadzadehfar H
PET Clin; 2021 Jul; 16(3):327-340. PubMed ID: 34053577
[TBL] [Abstract][Full Text] [Related]
31.
Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
[TBL] [Abstract][Full Text] [Related]
32. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
[TBL] [Abstract][Full Text] [Related]
33. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
[TBL] [Abstract][Full Text] [Related]
34. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
35. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
36. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Shore ND; Drake CG; Lin DW; Ryan CJ; Stratton KL; Dunshee C; Karsh LI; Kaul S; Kernen K; Pieczonka C; Sieber P; Stewart C; Williams M; Concepcion RS
Prostate; 2020 Oct; 80(14):1159-1176. PubMed ID: 32779781
[TBL] [Abstract][Full Text] [Related]
37. Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
Gómez Rivas J; Carrion DM; Alvarez-Maestro M; Cathelineau X; Sanchez-Salas R; Di Lorenzo G; Di Maio M; Paul A; Martinez-Piñeiro L; Sartor O; Saad F; Debruyne F
Minerva Urol Nefrol; 2019 Oct; 71(5):445-456. PubMed ID: 31353876
[TBL] [Abstract][Full Text] [Related]
38. Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.
Crombag MBS; de Vries Schultink AHM; van Doremalen JGC; Otten HM; Bergman AM; Schellens JHM; Beijnen JH; Huitema ADR
Drugs Aging; 2019 Apr; 36(4):379-385. PubMed ID: 30734241
[TBL] [Abstract][Full Text] [Related]
39. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
40. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
